| scholarly article | Q13442814 |
| P50 | author | María D Maciá | Q79793431 |
| P2093 | author name string | Gómez C | |
| Oliver A | |||
| Segura M | |||
| Pérez JL | |||
| Borrell N | |||
| P2860 | cites work | Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen | Q22122393 |
| Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy | Q24519008 | ||
| Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents | Q24550655 | ||
| A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance | Q28185783 | ||
| The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants | Q28492576 | ||
| Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia | Q29615286 | ||
| Lung infections associated with cystic fibrosis | Q30080000 | ||
| Escherichia coli mutator genes | Q33539352 | ||
| The biological cost of antibiotic resistance | Q33745219 | ||
| High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. | Q34508854 | ||
| Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy | Q35140423 | ||
| The mutant selection window and antimicrobial resistance | Q35153856 | ||
| Nosocomial infections in adult intensive-care units | Q35157647 | ||
| Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis | Q35557791 | ||
| Proliferation of mutators in A cell population | Q35618973 | ||
| Pseudomonal infections in patients with COPD: epidemiology and management | Q35627613 | ||
| Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC | Q35637864 | ||
| Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update | Q36072639 | ||
| Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. | Q36232237 | ||
| Dynamics of long-term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains | Q37421041 | ||
| Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections | Q37598703 | ||
| MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. | Q39743310 | ||
| Lack of association between hypermutation and antibiotic resistance development in Pseudomonas aeruginosa isolates from intensive care unit patients | Q39955018 | ||
| Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort | Q40412050 | ||
| Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies | Q40477935 | ||
| Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion | Q40968218 | ||
| Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation | Q41825397 | ||
| Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections | Q41974061 | ||
| Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test | Q43627836 | ||
| Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? | Q43874264 | ||
| Murine models of chronic Pseudomonas aeruginosa lung infection | Q44080662 | ||
| High Rate of Macrolide Resistance inStaphylococcus aureusStrains from Patients with Cystic Fibrosis Reveals High Proportions of Hypermutable Strains | Q44195004 | ||
| Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains | Q44786412 | ||
| Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputum | Q45044337 | ||
| Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair | Q46617407 | ||
| High mutation frequencies among Escherichia coli and Salmonella pathogens | Q48057867 | ||
| A modified Luria-Delbrück fluctuation assay for estimating and comparing mutation rates | Q50138265 | ||
| Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. | Q53592119 | ||
| Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. | Q54105307 | ||
| Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. | Q55066725 | ||
| Highly Variable Mutation Rates in Commensal and Pathogenic Escherichia coli | Q56944671 | ||
| Role of chronic Pseudomonas aeruginosa infection in the development of bronchiectasis | Q67574773 | ||
| Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis | Q71605414 | ||
| Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa | Q73400662 | ||
| Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis | Q74341827 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Pseudomonas aeruginosa | Q31856 |
| P304 | page(s) | 975-983 | |
| P577 | publication date | 2006-03-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa | |
| P478 | volume | 50 |
| Q37340607 | A global view of antibiotic resistance |
| Q36757725 | Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? |
| Q36933558 | Association between hypermutator phenotype, clinical variables, mucoid phenotype, and antimicrobial resistance in Pseudomonas aeruginosa |
| Q43153453 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants |
| Q37794342 | Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance |
| Q34491552 | Clinical significance of microbial infection and adaptation in cystic fibrosis |
| Q36095041 | Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro |
| Q31029779 | Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment. |
| Q41833848 | Effect of ciprofloxacin concentration on the frequency and nature of resistant mutants selected from Pseudomonas aeruginosa mutS and mutT hypermutators |
| Q90230125 | Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable Pseudomonas Aeruginosa Strains via Mechanism-Based Modelling |
| Q41366386 | Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation |
| Q40056971 | Genomics and Susceptibility Profiles of Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa from Spain. |
| Q36337074 | Global fluoroquinolone resistance epidemiology and implictions for clinical use. |
| Q42560500 | Inactivation of the mismatch repair system in Pseudomonas aeruginosa attenuates virulence but favors persistence of oropharyngeal colonization in cystic fibrosis mice. |
| Q35879111 | Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. |
| Q35065847 | Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets |
| Q37302114 | Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase. |
| Q36887819 | Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa |
| Q26825326 | Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer |
| Q34297656 | Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients |
| Q38006032 | Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections |
| Q37002813 | Predicting antibiotic resistance |
| Q36421553 | Pseudomonas aeruginosa RsmA plays an important role during murine infection by influencing colonization, virulence, persistence, and pulmonary inflammation |
| Q38268531 | Pseudomonas aeruginosa biofilm infections: from molecular biofilm biology to new treatment possibilities. |
| Q89531520 | Quantitative Models of Phage-Antibiotic Combination Therapy |
| Q36228925 | Real-Time Monitoring of nfxB Mutant Occurrence and Dynamics in Pseudomonas aeruginosa Biofilm Exposed to Subinhibitory Concentrations of Ciprofloxacin |
| Q36744840 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| Q33876563 | Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa |
| Q35939649 | Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections. |
| Q42572942 | Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa |
| Q33386642 | The Pseudomonas aeruginosa pfpI gene plays an antimutator role and provides general stress protection |
| Q38300820 | The problems of antibiotic resistance in cystic fibrosis and solutions |
| Q83386827 | [Microbiological diagnosis of bronchopulmonary colonization-infection in cystic fibrosis] |
Search more.